BR0011521B8 - compostos nucleósidos de purina de 4 -c-etinila - Google Patents

compostos nucleósidos de purina de 4 -c-etinila

Info

Publication number
BR0011521B8
BR0011521B8 BRPI0011521A BR0011521A BR0011521B8 BR 0011521 B8 BR0011521 B8 BR 0011521B8 BR PI0011521 A BRPI0011521 A BR PI0011521A BR 0011521 A BR0011521 A BR 0011521A BR 0011521 B8 BR0011521 B8 BR 0011521B8
Authority
BR
Brazil
Prior art keywords
ethinyl
purine nucleoside
nucleoside compounds
hydrogen atom
compounds
Prior art date
Application number
BRPI0011521A
Other languages
English (en)
Other versions
BR0011521A (pt
BR0011521B1 (pt
Inventor
Kodama Eiichi
Mitsuya Hiroaki
Ohrui Hiroshi
Kitano Kenji
Matsuoka Masao
Kohgo Satoru
Original Assignee
Yamasa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamasa Corp filed Critical Yamasa Corp
Publication of BR0011521A publication Critical patent/BR0011521A/pt
Publication of BR0011521B1 publication Critical patent/BR0011521B1/pt
Publication of BR0011521B8 publication Critical patent/BR0011521B8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals

Abstract

patente de invenção "compostos nucleósidos de purina de 4'-c-etinila". representados pela fórmula [i]: em que b representa uma base selecionada a partir do grupo que consiste de purina e seus derivados; x representa um átomo de hidrogênio ou um grupo hidroxila; e r representa um átomo de hidrogênio ou um resíduo de fosfato; e uma composição farmacêutica que contém qualquer dos compostos e um veículo farmaceuticamente aceitável. preferencialmente, a composição é utilizada como agente anti-hiv ou uma droga para o tratamento da aids.
BRPI0011521A 1999-05-12 2000-05-11 compostos nucleósidos de purina de 4 -c-etinila BR0011521B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP13153999 1999-05-12
JP17492099 1999-06-22
JP31824699 1999-11-09
JP2000081117 2000-03-23
PCT/JP2000/003025 WO2000069877A1 (en) 1999-05-12 2000-05-11 4'-c-ethynyl purine nucleosides

Publications (3)

Publication Number Publication Date
BR0011521A BR0011521A (pt) 2002-03-26
BR0011521B1 BR0011521B1 (pt) 2013-12-24
BR0011521B8 true BR0011521B8 (pt) 2021-05-25

Family

ID=27471622

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0011521A BR0011521B8 (pt) 1999-05-12 2000-05-11 compostos nucleósidos de purina de 4 -c-etinila

Country Status (10)

Country Link
US (3) US6291670B1 (pt)
EP (2) EP1177202B1 (pt)
AT (2) ATE250622T1 (pt)
AU (2) AU4431300A (pt)
BR (1) BR0011521B8 (pt)
CA (2) CA2308192C (pt)
DE (2) DE60005501T2 (pt)
ES (1) ES2207504T3 (pt)
MX (1) MXPA01011517A (pt)
WO (2) WO2000069876A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60005501T2 (de) * 1999-05-12 2004-06-24 Yamasa Corp., Choshi 4'-c-ethynyl-pyrimidine nukleoside
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
US20040006002A1 (en) * 2001-09-28 2004-01-08 Jean-Pierre Sommadossi Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside
JPWO2003068796A1 (ja) * 2002-02-15 2005-06-02 ヤマサ醤油株式会社 4’−c−シアノ−2’−デオキシプリンヌクレオシド
US7589078B2 (en) 2003-02-19 2009-09-15 Yale University Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections
CA2502109C (en) * 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
US7645459B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
EP1794172B1 (en) 2004-08-23 2009-07-15 F.Hoffmann-La Roche Ag Antiviral 4'-azido-nucleosides
EA200800932A1 (ru) * 2005-09-26 2008-10-30 Фармассет, Инк. Модифицированные 4`-нуклеозиды в качестве противовирусных агентов
CN101573370B (zh) 2006-10-10 2013-09-11 美迪维尔公司 Hcv核苷类抑制剂
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
UY34536A (es) * 2011-12-22 2013-07-31 Alios Biopharma Inc Nucleósidos sustituidos, nucleótidos y análogos de los mismos
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
SG11201602595TA (en) 2013-10-11 2016-04-28 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
WO2015143712A1 (en) 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
WO2017053216A2 (en) 2015-09-23 2017-03-30 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors and preparations thereof
EP3543238B1 (en) 2016-11-16 2021-05-19 National Center for Global Health and Medicine Nucleoside derivatives having anti-viral activity
US11040975B2 (en) 2017-12-08 2021-06-22 Merck Sharp & Dohme Corp. Carbocyclic nucleoside reverse transcriptase inhibitors
CN111971284A (zh) * 2017-12-27 2020-11-20 埃默里大学 核苷和/或nadph氧化酶(nox)抑制剂作为髓样特异性抗病毒剂的联合模式
MX2021000278A (es) * 2018-07-09 2021-03-31 Merck Sharp & Dohme Llc Sintesis enzimatica de analogos de nucleosido de 4'-etinilo.
US20210323993A1 (en) * 2018-08-30 2021-10-21 Glaxosmithkline Intellectual Property (No. 2) Limited Compounds Useful in HIV Therapy
SG11202107145SA (en) 2019-01-25 2021-08-30 Univ Brown Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
WO2021038509A1 (en) * 2019-08-28 2021-03-04 Glaxosmithkline Intellectual Property (No.2) Limited 4'-ethynyl-2'-deoxyadenosine derivatives and their use in hiv therapy
EP4121437A1 (en) 2020-03-20 2023-01-25 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60005501T2 (de) * 1999-05-12 2004-06-24 Yamasa Corp., Choshi 4'-c-ethynyl-pyrimidine nukleoside

Also Published As

Publication number Publication date
MXPA01011517A (es) 2003-08-20
EP1177201B1 (en) 2003-09-24
DE60005501D1 (de) 2003-10-30
ES2207504T3 (es) 2004-06-01
WO2000069877A1 (en) 2000-11-23
DE60005502D1 (de) 2003-10-30
EP1177202B1 (en) 2003-09-24
AU4431300A (en) 2000-12-05
CA2308192C (en) 2007-09-18
CA2308677C (en) 2007-09-18
EP1177201A1 (en) 2002-02-06
US6291670B1 (en) 2001-09-18
AU4431200A (en) 2000-12-05
BR0011521A (pt) 2002-03-26
CA2308677A1 (en) 2000-11-12
US20020022722A1 (en) 2002-02-21
WO2000069876A1 (en) 2000-11-23
DE60005502T2 (de) 2004-06-24
DE60005501T2 (de) 2004-06-24
US6403568B1 (en) 2002-06-11
ATE250623T1 (de) 2003-10-15
BR0011521B1 (pt) 2013-12-24
ATE250622T1 (de) 2003-10-15
EP1177202A1 (en) 2002-02-06
US6333315B1 (en) 2001-12-25
CA2308192A1 (en) 2000-11-12

Similar Documents

Publication Publication Date Title
BR0011521B1 (pt) Compostos nucleósidos de purina de 4 -c-etinila
ES2175079T3 (es) Derivados de indol utiles como inhibidores de cgmp-pde.
AP2002002455A0 (en) 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dIhydropyrazolo[4,3-D] pyrimidin-7-ones as phosphodiesterase inhibitors.
BG106569A (en) Purine derivatives
WO2002069903A3 (en) Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
AP2002002480A0 (en) Purine derivatives.
UA66801C2 (uk) Триазоло[4,5-d]піримідинові сполуки, спосіб їх одержання (варіанти), фармацевтична композиція на їх основі та спосіб лікування порушень агрегації тромбоцитів
AP2001002361A0 (en) Purine derivatives.
EP1334719A3 (en) Pentafluorobenzenesulfonamides and analogs
AP9801378A0 (en) 9-amino-3- keto erythromycin derivatives.
TR200103395T2 (tr) 13-metil eritromisin türevleri.
DE60101223D1 (de) Antivirale pyrimidin nucleoside derivate
GEP20084284B (en) Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
MY105523A (en) Substituted-1,3-oxathiolanes with antiviral properties.
SE9904129D0 (sv) Novel compounds
CA2238875A1 (en) Tri-aryl ethane derivatives as pde iv inhibitors
RS20050450A (en) 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists
DE69031340T2 (de) 3'-azido-2',3'-dideoxy-5-methylcytidin enthaltende antivirale zusammensetzungen
ATE251162T1 (de) Triazolo(4,5-d)pyrimidin-verbindungen
ZA981430B (en) Anticancer composition
AU7653300A (en) Carbocyclic nucleosides and process for obtaining such
IL147307A0 (en) Indolocarbazole alkaloid derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
ES2128960A1 (es) Derivados de fluorofenil-triazinas y pirimidinas compuestos farmacologicamente activos en el sistema nervioso central.
HUP0101505A2 (hu) Barbitursavszármazékok és ezeket tartalmazó gyógyszerkészítmények csont- és porcbetegségek kezelésére és megelőzésére
CA2239053A1 (en) Diphenyl pyridyl ethane derivatives as pde iv inhibitors

Legal Events

Date Code Title Description
B08E Application fees: payment of additional fee required [chapter 8.5 patent gazette]

Free format text: COMPLEMENTAR A RETRIBUICAO DA(S) 7A ANUIDADE(S), DE ACORDO COM A TABELA VIGENTE, REFERENTE A(S) GUIA(S) NO 220602446160.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: REFERENTE A RPI NO 2116 DE 26/07/2011

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DA 10A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08G Application fees: restoration [chapter 8.7 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/12/2013, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/05/2000 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 11/05/2020